Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
The phase II MyeloMATCH trial evaluates whether experimental regimens—including daunorubicin and cytarabine liposome alone, cytarabine plus venetoclax, azacitidine plus venetoclax, and daunorubicin and cytarabine liposome with venetoclax—are more effective at eliminating acute myeloid leukemia (AML) than the standard cytarabine and daunorubicin combination.
The MyeloMATCH clinical trial (Phase II) compares the standard cytarabine and daunorubicin regimen to several experimental treatments in adults aged 18–59 with newly diagnosed, untreated high‑risk AML. Experimental arms include cytarabine liposome alone, cytarabine plus venetoclax, azacitidine plus venetoclax, and daunorubicin and cytarabine liposome with venetoclax. The study aims to determine whether these novel therapies can achieve a higher rate of disease clearance compared with the established chemotherapy backbone.
High‑risk AML has poor prognosis with conventional therapy. Demonstrating superior efficacy of new regimens could improve remission rates and overall survival for patients who otherwise have limited treatment options.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- Lymphoma Clinical Trials and Research
- Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial
- Englumafusp alfa plus glofitamab in B cell non‑Hodgkin lymphoma: a phase 1 trial